![]() ![]() Unfortunately, CBO’s analysis appears to have significantly underestimated the impact and consequences from the IRA’s price controls on drug development and innovation. The Congressional Budget Office (CBO) estimated government drug price controls in the IRA would result in two fewer drugs being brought to market over the next decade, five fewer drugs in the subsequent decade, and eight fewer drugs in the decade after that.
0 Comments
Leave a Reply. |